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Abstract
Background: Endothelin-1 (ET-1), a long-acting paracrine mediator, is implicated in cardiovascular diseases but clinical trials
with ET-receptor antagonists were not successful in some areas. We tested whether the quasi-irreversible receptor-binding
of ET-1 (i) limits reversing effects of the antagonists and (ii) can be selectively dissociated by an endogenous
counterbalancing mechanism.
Methodology/Principal findings: In isolated rat mesenteric resistance arteries, ETA-antagonists, endothelium-derived
relaxing factors and synthetic vasodilators transiently reduced contractile effects of ET-1 but did not prevent persistent
effects of the peptide. Stimuli of peri-vascular vasodilator sensory-motor nerves such as capsaicin not only reduced but also
terminated long-lasting effects of ET-1. This was prevented by CGRP-receptor antagonists and was mimicked by exogenous
calcitonin gene-related peptide (CGRP). Using 2-photon laser scanning microscopy in vital intact arteries, capsaicin and
CGRP, but not ETA-antagonism, were observed to promote dissociation of pre-existing ET-1/ETA-receptor complexes.
Conclusions: Irreversible binding and activation of ETA-receptors by ET-1 (i) occur at an antagonist-insensitive site of the
receptor and (ii) are selectively terminated by endogenously released CGRP. Hence, natural stimuli of sensory-motor nerves
that stimulate release of endogenous CGRP can be considered for therapy of diseases involving ET-1.
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Introduction
Prototypic G-protein coupled receptors (GPCR) are characterized
by tight agonist concentration-response relationships on the short run
and by tolerance on the long run. For instance, acute b2-
adrenoceptor stimulated cAMP production and the resulting smooth
muscle relaxation are readily reversible as a result of rapid
dissociation of the agonist-receptor complexes. This property
underlies the therapeutic applicability of drugs that inhibit the
synthesis or the receptor-binding of endogenous GPCR-agonists.
During prolonged exposure to agonists, b2-adrenergiceffectsfadeasa
result of phosphorylation, desensitization, uncoupling from the G-
proteins and internalization of the receptors (for review see [1]).
In sharp contrast, the GPCR-agonist endothelin-1 (ET-1) causes
long-lasting effects. Its in vitro arterial contractile effects persist
after thorough washout of the agonist[2]. Its in vivo vasopressor
effects are maintained long after clearance of the peptide from the
circulation by the lungs and the kidneys[3]. The 21 amino acid
bicyclic peptide, that is constitutively expressed by the endothe-
lium and that can be induced in several other cell types[4,5], is
implicated in several cardiovascular diseases[4,6,7], cancers[8]
and pain[9]. Its vasoconstrictor, pro-inflammatory, oxidative and
mitogenic effects are mediated by ETA-receptors[4,6,7] while
more beneficial effects such as endothelium-dependent vasodila-
tation and scavenging of circulating ET-1 are mediated by
distantly related ETB-receptors[4,5,6,7,10]. ETB-agonism can be
mimicked by short C-terminal fragments of ET-1[11,12,13] but
high affinity ETA-agonism requires the full length, both disulfide
bonds and distinct amino acids in the N-terminal loop of the
peptide[12,14,15,16,17,18]. This suggests that distinct parts of ET-
1 have different functions in binding and activation of ETA-
receptors. Several classes of low molecular weight ETA-selective or
mixed ET-receptor antagonists have been developed primarily on
the basis of prevention of the binding of ET-1 to its recep-
tors[4,5,6,19,20,21]. These compounds are thought to compete
with the C-terminal tail of the agonist. They can prevent ET-1-
induced effects in vitro (for review see [2]) and in animal
studies[4,6,19]. They are, however, less effective in reversing the
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trials[6,23]. This may be due to the atypical properties of
ETA-receptors.
Irreversible agonism by ET-1 is incompatible with homeostasis
unless counterbalancing systems exist. ET-1 can stimulate NO
release from the endothelium[24]. NO reduces ET-1 synthesis[25]
and counteracts vasoconstriction initiated by ETA-receptors on
smooth muscle cells[4,7,26]. ET-1 can also promote activity of
transient receptor potential (TRP) cation channels that stimulate
release of vasodilator neurotransmitters from peri-arterial sensory-
motor nerves (SMN)[27,28]. Hence, in cardiovascular diseases
characterized by reduced bioavailability of endothelium-derived
NO, ET-1 and ETA-effects are upregulated[4] and can be
tempered by counterbalancing effects of SMN[29,30,31]. Whether
the latter involves functional antagonism or a selective effect on
ETA-receptors has not been addressed.
In this study, we hypothesized that polyvalent agonist-receptor
binding by ET-1 limits reversing effects of ET-receptor antagonists
and used physiological reasoning to search for a superior inhibitor.
For these purposes we studied rat mesenteric arteries in which
ETA- and ETB-receptors are expressed by several cell
types[31,32,33]. We discovered that calcitonin-gene related
peptide (CGRP) released from peri-arterial SMN terminates
long-lasting vasoconstrictor effects of ET by promoting dissocia-
tion of ET-1/ETA-receptor complexes.
Results
Key role of smooth muscle ETA-receptors in long-lasting
arterial contractile responses to ET-1
In isolated rat mesenteric resistance arteries, the ETB-selective
agonist Ala
1,3,11,15-ET-1[10] (1 nM–1 mM) caused neither con-
traction (Table 1) nor relaxation (data not shown). In contrast, the
non-selective agonist ET-1[10] potently stimulated contractions
(Fig. 1A, table 1). The concentration-response relationship was
steep and the responses were quasi-irreversible (T1/2 .20 min
versus T1/2 <30 sec for similarly strong contractile responses to
norepinephrine (NE) (Fig. 1A/B). Contractile effects of ET-1 and
their persistence were not modified by 1 mM BQ788 (ETB-
antagonist)[10,34], 100 mM L-NAME and 10 mM indomethacin
(which reduce endothelial influences), nor by pre-treatment with
capsaicin (1 mM during 20 min, which reduces effects of SMN)
(Fig. 1A and table 1). Mechanical removal of the endothelium
resulted in a small increase in the sensitivity for ET-1 (Table 1).
The sensitivity to ET-1 was reduced in presence of the ETA-
antagonists BQ123[10,35] (1 mM), SB234551[10,21] (10 nM) or
bosentan[10,19] (3 mM studied in presence of 1 mM BQ788 to
focus on ETA-antagonism by boseantan, a mixed ETA/B-receptor
antagonist) (Fig. 1A, Fig. S1A).
Partial and transient reversing effects of ETA-antagonists
Although BQ123, SB234551 and bosentan prevented contrac-
tile responses to up to 8 nM ET-1, the antagonists could only
partly (<50%) reverse contractile responses initiated by 8 nM ET-
1 (Fig. 1C, Fig. S1C). The relaxing effect of the antagonists was
reversible, i.e. vasomotor tone rapidly recovered after washout of
the ET-receptor ligands (Fig. 1D, Fig. S1D). This indicates
irreversible agonism and reversible antagonism. In addition,
contractile effects of ET-1 that persisted in absence of free agonist
were partly and transiently reduced by the antagonists (Fig. 1E/F,
Fig. S1E/F).
Transient reversing effects of endothelium-derived and
exogenous vasodilators
In contrast to ET-antagonists, several vasodilator stimuli fully
reversed contractile responses to ET-1 (Fig. 2A). This was the case
for acetylcholine (endothelium-dependent vasodilator), forskolin
(direct activator of adenylyl cyclase), isoproterenol (beta-adrenergic
stimulus of adenylyl cyclase), Na-nitroprusside (NO-donor) and
pinacidil (activator of KATP-channels) (Fig. 2C). However,
vasomotor tone rapidly recovered in absence of vasodilators and
ET-1 (Fig. 2D). Moreover, contractions remaining after exposure
to ET-1 could be relaxed by for instance acetylcholine (Fig. 3B)
but again this inhibitory effect was reversible (Fig. 3C).
Effects of TRP-channel activators and CGRP
In contrast to these vasodilators, capsaicin relaxed ET-1-
induced contractions (Fig. 2B/C) and prevented their recovery
(Fig. 2B/D). This was also observed with rutaecarpine and with
allyl isothiocyanate (Fig. 4A/B). In the case of rutaecarpine these
effects were endothelium independent (Fig. S2). Capsaicin,
rutaecarpine and allyl isothiocyanate stimulate release of several
neurotransmitters from SMN[27,36,37,38,39,40]. The CGRP-
receptor antagonists CGRP8-37[41] (1 mM) and BIBN4096BS[42]
(20 nM)) reduced both the relaxation and the prevention of
persistent effects of ET-1 by the SMN stimuli (Fig. 2C/D, Fig. 4A/
B). Moreover, exogenous CGRP relaxed ET-1-induced contrac-
tions (Fig. 2C), prevented recovery of contractions initiated by ET-
1 (Fig. 2D) and caused long-lasting inhibition of the persistent
effects initiated by ET-1 (Fig. 3A/B). These effects were
endothelium independent (Fig. S2) and were reduced by CGRP-
receptor antagonists (Fig. 2C/D). The contraction that persisted
after exposure to ET-1 and that was transiently inhibited by ET-
Table 1. Arterial effects of ET-1 and two analogues.
Agonist Condition EC50 (nM) Emax (% NEmax)
Tension (%NEmax; 8 min after agonist
removal)
ET-1 - 4.960.8 88.564.0 80.963.5
Denuded 2.160.2 * 100.166.2 82.5465.4
L-NAME + INDO 3.560.5 100.465.0 79.263.3
CAPS + L-NAME + INDO 3.660.3 104.064.0 84.5614.0
Rh-ET-1 CAPS + L-NAME + INDO 4.160.3 102.0610.0 80.6614.6
Ala
1,3,11,15-ET-1 CAPS + L-NAME + INDO .1 mM0 0
Potency, efficacy and persistence (response remaining at 8 min after agonist removal) are shown for arteries without and with pre-treatment with capsaicin (1 mM,
20 min; CAPS) and presence of L-NAME (100 mM) and indomethacin (10 mM; INDO) and for denuded arteries. n=6–10. *: p,0.05 vs control.
doi:10.1371/journal.pone.0010917.t001
CGRP Terminates ET-1/ETA
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was terminated by capsaicin and by CGRP (Fig. 3B/C).
When arteries were transiently exposed to a high concentration
of CGRP (100 nM; Fig. 5A) or to ET-1 (16 nM) and then to
CGRP (100 nM; Fig. 5B), exogenous ET-1 (1–16 nM; applied
after removing other vasoactive compound from the organ bath)
caused contractions with a potency and an efficacy that deviate
only marginally from those observed in controls (Fig. 5C/D). This
suggests that CGRP does not induce a long-lasting relaxing effect
(Fig. 5C) but rather promotes dissociation of previously established
ET-1/ETA-receptor complexes allowing re-application of ET-1 to
again induced contractile responses (Fig. 5D).
Modulation of ET-1/ETA-receptor binding
We used rhodamine-labeled ET-1 (Rh-ET-1) and two-photon
laser scanning microscopy (TPLSM) focusing on the tunica media,
to visualize binding of ET-1 to the smooth muscle. Contractile
properties did not differ between Rh-ET-1 and ET-1 (Table 1).
Binding of Rh-ET-1 (16 nM) to smooth muscle (Fig. 6D) was
reduced by BQ788 (1 mM; Fig. 6E) and was prevented by presence
of either ET-1 (16 nM) or of both BQ788 (1 mM) and BQ123
(1 mM)[2] indicating selective binding to ETA- and ETB-receptors.
Once established, binding of Rh-ET-1 persisted after washout of
free Rh-ET-1 and was not reversed by BQ123 (1 mM; Fig. 6F)
indicating quasi-irreversible receptor-binding of the agonist. In
contrast, capsaicin (1 mM) and exogenous CGRP (100 nM;
investigated in presence and absence (not shown) of 1 mM
BQ788), reversed the binding of Rh-ET-1 to smooth muscle that
remained after exposure to Rh-ET-1 (Fig. 6I/M). Thereafter, Rh-
ET-1 could again label the arterial smooth muscle (Fig. 6J/N).
Discussion
The novel finding of our work is that while ET-receptor
antagonists partly and transiently reduce endothelinergic vaso-
constriction as a result of bitopic and irreversible agonist-receptor
binding, stimuli of SMN can terminate effects initiated by ET-1
through CGRP-receptors that promote dissociation of ET-1/ETA-
receptor complexes. This may lead to novel therapies of diseases
involving ET-1.
We compared effects and mechanisms of action of competitive
and physiological antagonists of ET-1 in isolated rat mesenteric
resistance arteries. In these vessels, which influence local blood
flow and total peripheral resistance and contribute to the
development of hypertension[43], ET-receptor subtypes are
expressed by several cell types[31,32,33]. However, a selective
Figure 1. Partial and reversible reversing effect of ET-receptor antagonists on arterial contractile responses to ET-1 and their
persistence. Isolated rat mesenteric resistance arteries were studied after treatment with capsaicin and in continuous presence of L-NAME (100 mM)
and indomethacin (10 mM). A, responses to 0.25–16 nM ET-1 in absence (black) and presence of BQ123 (1 mM, red), BQ788 (1 mM, grey) or bosentan
(3 mM in presence of 1 mM BQ788, blue). BQ123 and bosentan prevented responses to up to 8 nM ET-1. B, vasomotor tone after removal of free
agonist and antagonist. C, effects of BQ123 and bosentan (0.1–3.0 mM) in the presence of 8 nM ET-1. D, vasomotor tone after removal of free agonist
and antagonist. E, effect of BQ123 (1 mM) and bosentan (3 mM) on contractile responses initiated by 8 nM ET-1 that persisted in absence of the
peptide. F, vasomotor tone after removal of free antagonist. n=6–20. *, P,0.05 vs. control.
doi:10.1371/journal.pone.0010917.g001
CGRP Terminates ET-1/ETA
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ET-1 were not modified by an ETB-antagonist, pre-treatment with
capsaicin or inhibition of NO-synthases and cyclo-oxygenases.
Thus, initiation and maintenance of contractile responses to ET-1
were dominated by smooth muscle ETA-receptors and were hardly
affected by basal or endothelinergic influences of SMN or the
endothelium.
Ligand-binding studies and analyses of structure-affinity and
structure-selectivity relationships previously indicated quasi-irre-
versible and polyvalent binding of ET-1 to ETA-recep-
tors[2,5,15,17,44,45]. The high affinity of ET-1 for ETA-receptors
is due to slow dissociation of the agonist-receptor complexes[2].
ET-1 requires the C-terminal Trp
21, both disulphide bonds and
distinct amino acids in the N-terminal loop for high affinity
binding to ETA-receptors[2,5,12,13,14,15,18]. It has therefore
been proposed that several parts of ET-1 interact with distinct sites
on the ETA-receptor[15,17]. To the best of our knowledge, the
consequences of this polyvalent and irreversible binding of ET-1 to
ETA-receptors for signaling have not been addressed before. We
show that ETA-antagonists can prevent binding and contractile
effects of ET-1 but that they are less effective in reversing effects
induced by ET-1. This discrepancy has also been observed in vivo
(e.g. [22]) and was even more marked in an in vitro study using
another ETA-antagonist [46]. In addition, we report that ET-
receptor antagonists reduce not only responses in presence of ET-1
but also responses that had been initiated by ET-1 and that
persisted in absence of free agonist. These findings combined with
earlier models of ETA-receptor function [15,17] can be integrated
into a model regarding ET-1/ETA-interactions and ETA-mediat-
ed signaling as depicted in Fig. 7. A part of ET-1, and the low
Figure 2. Capsaicin and CGRP relax endothelinergic arterial contraction and prevent the persistent contractile effect of ET-1.
Isolated rat mesenteric resistance arteries were studied in presence of L-NAME (100 mM) and indomethacin (10 mM) (as indicated) and were
contracted with ET-1 (16 nM). Increasing vasodilator concentrations were administered until a maximal effect was observed. Thereafter
vasoconstrictor and vasodilator stimuli were removed from the organ chamber while the recording of active wall tension continued for .10 min. A
and B, typical tracings of active wall tension (WT) versus time (t) illustrating acute relaxing effects (green box) of acetylcholine (A; 0.01–10 mM) and
capsaicin (B; 0.01–1 mM) and rapid recovery of contraction after removal of the vasodilator (long-term effect, red box) in the case of acetylcholine (A)
but not capsaicin (B). C, maximal acute relaxing effects of various dilators. D, long-term effects of various dilators. a, time control; b and c,
acetylcholine; d, isoproterenol; e, forskolin; f, Na-nitroprusside; g, pinacidil; h – j, capsaicin in the absence (h) and presence of CGRP8-37 (i) or
BIBN4096BS (j); k - m, CGRP in the absence (k) and presence of CGRP8-37 (l) or BIBN4096BS (m). For concentrations of vasodilators see ‘‘Methods’’
section. n=6–8. *, $ and #:P ,0.05 vs. control, capsaicin or CGRP, respectively.
doi:10.1371/journal.pone.0010917.g002
CGRP Terminates ET-1/ETA
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binding site on the receptor (site H). Thereafter another part of the
ET-1 molecule binds to a second distinct binding-site on the
receptor (site L). Binding of ET-1 at site H is dynamic and remains
susceptible to competition by the low molecular weight antago-
nists. It precedes and is required for binding at site L which (i) is
insensitive to antagonists, (ii) triggers signalling and (iii) binds the
agonist quasi-irreversibly. This model explains the lower potency
than affinity and the steepness of the concentration-effect
relationships of ET-1 when signaling by ETA-receptors is
enhanced by cooperativity between the two binding sites of ET-
1. In addition, it takes into account the flexibility of ET-1 as
indicated by X-ray crystallography and NMR spectroscopy studies
[47,48] and displays similarities to the ‘‘address and message
domain model’’ proposed for other GPCR agonists [49,50].
Because similar findings were obtained with BQ123, SB234551
and bosentan which represent i) hydrophilic and lipophilic
antagonists and ii) ETA-selective and mixed antagonists, internal-
ization and heterodimerization of receptors do not seem to be
involved.
Our model predicts that compounds which accelerate dissoci-
ation of ET-1/ETA-receptor complexes have a larger and more
long-lasting inhibitory effect on responses initiated by ET-1
compared to neutral competitive antagonists. Aspirin-like mole-
cules were reported to display such an allosteric inhibitory effect at
millimolar concentrations[45,51]. We focused on the endothelium
and on SMN, two structures that counterbalance ET-1/ETA-
effects in vivo [4,7,25,29,30,31], to identify a similar but more
potent mechanism. The endothelium-dependent vasodilator
acetylcholine and several directly acting vasodilators fully relaxed
ET-1-induced contractions. However, these relaxations were
transient and did not inhibit the persistent contractile effect
initiated by ET-1. This indicates mere functional antagonism. In
contrast, stimuli of SMN not only reversed ET-1-induced
contractions but also prevented their recovery. This was observed
with capsaicin (pungent vanilloid TRPV1-stimulus of Capsicum
Spec[40]), rutaecarpine (an alkaloid TRPV1-agonist from the
chinese traditional medicinal herb Evodia Rutaecarpa[39]) and with
allyl isothiocyanate (an organosulfur TRPA1-channel activator of
Allium and Brassica[37]). For rutaecarpine the effects were not
modified by removal of the endothelium excluding a role for
endothelial TRPV1-channels[52]. The effects of SMN-stimuli
were reduced by CGRP-receptor antagonists and mimicked by
exogenous CGRP, a neurotransmitter that can be released from
peri-arterial SMN [27,36,40]. However, they could not be
reproduced by agents that stimulate adenylyl cyclase (forskolin
and isoproterenol), generate NO (Na-nitroprusside) or open KATP-
channels (pinacidil) and thus activate components of the classical
signal-transduction mechanism triggered by CGRP-receptors (for
review see [53]). Furthermore, the contractile potency and efficacy
of ET-1 were hardly modified by pre-exposure to capsaicin or
CGRP or after ‘‘termination’’ of the persistent effect of ET-1 by
CGRP. This suggests that the cAMP-independent effect of CGRP
against ET-1 involves dissociation of ET-1/ETA-receptor com-
plexes and not a long-lasting relaxing effect. Clearly, this invites for
further investigations into the molecular mechanism(s) induced by
CGRP in this setting. These studies should focus on possibilities
like i) heterodimers between ETA- and CGRP-receptors, ii) rapid
phosphorylation followed by desensitization of ETA-receptors
mediated by e.g. G protein receptor kinases [54], which can be
activated by CGRP-receptor stimulation [55] and iii) possible
interactions between the different subunits of CGRP receptors,
most notably receptor activity modifying protein 1, and ETA-
receptors. We used imaging to study the effects of CGRP-receptor
Figure 3. Capsaicin, CGRP and acetylcholine relax endothelinergic arterial contraction that remained after removal of ET-1 from its
biophase but only capsaicin and CGRP prevent the persistent contractile effect of ET-1. A, schematic tracings of active wall tension (WT)
versus time (t) illustrating i) ET-1-induced contractions that are not reversed upon agonist removal (W), ii) acute effects of various dilators and iii)
prevention of long-term ET-1 effects by capsaicin (purple) and CGRP (blue) but not acetylcholine (grey). B, maximal acute relaxing effects of
acetylcholine (b), capsaicin (c) or CGRP (d). C, long-term effects of acetylcholine (b), capsaicin (c) or CGRP (d). For concentrations of vasodilators see
‘‘Methods’’ section. n=6–8. *: P,0.05 vs. control.
doi:10.1371/journal.pone.0010917.g003
CGRP Terminates ET-1/ETA
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receptors. In line with earlier findings, fluorescent labeling of ET-1
at Lys
9 did not modify the pharmacology of the agonist [2,56,57].
We observed intense staining of intact vascular smooth muscle
which could be prevented by ET-1 and by combined ETA- and
ETB-antagonism ([2] and this study). Thus, we show that ET-1
agonist-receptor binding can be visualised in a vital tissue without
the need for supra-physiological receptor densities. Compared to
conventional radioligand binding experiments with microsomes or
intact arteries (e.g. [58] it has the added value that (i) small tissue
samples can be used efficiently without the need for large numbers
of arteries and animals, (ii) dissociation of ET-1/ETA-complexes
can be monitored in real-time and (iii) effects of second messengers
and endogenously released mediators (e.g. neurotransmitters) can
be registered. In line with the model that we propose, labeling of
vascular smooth muscle persisted after removal of free label. In
addition, labeling was not reversed by BQ123 in the presence of
BQ788. In contrast, capsaicin and CGRP each abolished pre-
existing labeling. Thereafter, Rh-ET-1 could again label the
smooth muscle with comparable intensity. This strengthens the
conclusion that CGRP-receptor stimulation promotes dissociation
of the agonist ET-1 from contractile ETA-receptors.
In summary (Fig. 7), CGRP released from SMN promotes the
dissociation of the ET-1/ETA-receptor complexes that are respon-
sible for the long-lasting effects of the peptide. Hence CGRP can be
moresuited toinhibit vasculareffectsofET-1 compared to functional
antagonists and competitive antagonists. We could not demonstrate
that this mechanism acts as a negative feedback under normal
conditions because desensitization of SMN and presence of CGRP-
receptor antagonists do not alter the sensitivity to ET-1 ([33] and this
study). This is in line with observations that ET-1 does not directly
stimulate but modulates effects of TRP channel activators[27,28].
The negative feedback may become operative during ischemia and
inflammation which stimulate SMN activity. Several other aspects
remain to be addressed to validate CGRP-receptor agonism and
SMN as valid targets for therapy of ET-1-related diseases. These
include effects of SMN and CGRP against endogenously produced
ET-1 in other vessels and other species. In the mean time it may be
worthwhile to consider how widely available natural and orally active
stimuli of SMN could be applied in diseases that involve ET-1 but in
which clinical efficacy of ET-receptor antagonists has been hard to
prove [6,23].
Materials and Methods
Experimental protocols were approved by the Ethics Commit-
tee on Experimental Animal Welfare of Maastricht University.
Solutions and Drugs
Bosentan[19], BIBN4096BS[42] and SB-234551[21] were ob-
tained from Actelion Pharmaceuticals (Allschwill, CH), Boehringer
Ingelheim Pharma KG (Biberach, D) and GlaxoSmithKline
(Stevenage, UK) respectively, and dissolved in DMSO. Allyl
isothiocyanate[37], capsaicin[38,40], forskolin and indomethacin
were purchased from Sigma Aldrich (Zwijndrecht, NL) and dissolved
in ethanol. Acetylcholine, isoproterenol, L-NAME (Nv (G)-nitro-L-
arginine methyl ester), Na-nitroprusside, norepinephrine, and
isoproterenol were purchased from Sigma Aldrich (Zwijndrecht,
NL) and dissolved in Krebs-Ringer bicarbonate (KRB) solution.
Pinacidil was obtained from Sigma Aldrich (Zwijndrecht, NL) and
dissolved in DMSO. BQ123[20] and BQ788[34] were obtained from
B a c h e m( W e i la mR h e i n ,D )a n dd i s s o l v e di nD M S O .H u m a n
CGRP, CGRP 8-37[
41], ET-1 and Ala1,3,11,15-ET-1[10] were
obtained from Bachem (Weil am Rhein, D) and dissolved in KRB
solution. Rutaecarpine[39] was a kind gift from Prof. Yu Huang
(Chinese University of Hong Kong, China) and was dissolved in
DMSO. The maximal concentrations of the solvents never exceeded
0.1% and did not alter arterial reactivity.
Tissue Preparation
16 weeks old male WKY rats (Charles River, Maastricht, NL)
were euthanized by CO2 inhalation. Second-order side branches
of the superior mesenteric artery were isolated, and either
mounted in a wire-myograph and stretched as previously
described [33,59] or mounted in a pressure-myograph and
pressurized at 80 mm Hg[27,60]. In some arteries, the endothe-
lium was mechanically removed[27,33,59].
Vasomotor responses
At optimal diameter (34066 mm) the contractile response to
10 mM NE averaged 4.160.2 N/m. The relaxing responses to
acetylcholine (10 mM) during this precontraction averaged
93.760.7% and was absent in denuded arteries.
Effects of ET-receptor antagonists. The effect of the ETA-
antagonists BQ123[20] (1 mM), bosentan[19] (3 mM, in presence of
BQ788 (1 mM)) or SB234551[21] (10 nM) was assessed when applied
Figure 4. Stimuli of SMN, like rutaecarpine and allyl isothio-
cyanate, relax endothelinergic arterial contraction and prevent
the persistent contractile effect of ET-1. Isolated rat mesenteric
resistance arteries were precontracted with 16 nM ET-1. Increasing
concentrations of vasodilator compounds were administered until a
maximal effect was observed. Thereafter vasoactive stimuli were
removed from the organ chamber while the recording of active wall
tension continued for .10 min. A, maximal acute relaxing effects of
rutaecarpine and allyl isothiocyanate. B, long-term effects of rutaecar-
pine and allyl isothiocyanate. a, time control; b, rutaecarpine; c,
rutaecarpine in presence of BIBN4096BS; d, allyl isothiocyanate; e, allyl
isothiocyanate in presence of BIBN4096BS. For concentrations of
vasodilators see ‘‘Methods’’ section. n=6–8. *, $ and #:P ,0.05 vs.
control, rutaecarpine and allyl isothiocyanate, respectively.
doi:10.1371/journal.pone.0010917.g004
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addition, the effect of increasing concentrations (0.1–3 mM) of
BQ123 and bosentan was assessed during contractions induced by
8 nM ET-1. Also, the effect of SB234551 (10 nM) during ET-1-
induced contraction (8 nM) was determined. Finally, the effect of the
antagonists was determined during contractions that remained after
removal of ET-1 from its biophase. Before these experiments, peri-
arterial SMN were desensitized[33,38,40]. In addition, L-NAME
(100 mM) and indomethacin (10 mM) were continuously present.
Effects of candidate functional antagonists. During ET-1-
induced contractions (16 nM),and duringcontractions that remained
after removal of ET-1 (16 nM) from its biophase, arterial relaxing
responses to increasing concentrations acetylcholine (0.01–10 mM),
capsaicin (0.01–1.0 mM), CGRP (0.1–100 nM), Na-nitroprusside
(0.01–10 mM), rutaecarpine (0.1–10 mM), allyl isothiocyanate (0.01–
10 mM), forskolin (0.1–3 mM), isoproterenol (0.01–3 mM) or pinacidil
(0.01–10 mM) were assessed. These experiments were performed in
absence of pharmacological inhibitors and were repeated in presence
of L-NAME (100 mM) and indomethacin (10 mM) and in
presence of CGRP-receptor antagonists (BIBN4096BS[42] (20 nM)
or aCGRP8-37[41]( 1mM)). Some of these experiments were repeated
in denuded arteries.
Synthesis of fluorescently labeled ET-1
0.35 mg ET-1 (0.14 mmol) was dissolved in 50 mL dimethylfor-
mamide +1 mL N,N-diisopropylethylamine. 50 mL Rhodamine-
succinimidyl ester (Rh-SE) stock solution (6.3 mmol/ml 33%
acetonitril/67% methanol) was added and left overnight for
coupling. After 16 hours HPLC and MALDI-TOF analyses
showed that .90% of ET-1 was mono-labeled. Rh-ET-1 was
purified using semi-preparative reversed-phase HPLC using a
Vydac C-18 column (250610 mm, 10 mm). A lineair gradient of
acetonitrile in water/0.1% TFA (flow rate 5 ml/min; 0.5%B/min)
was applied to elute peptides. Rh-ET-1 was lyophilized and stored
at 220uC until use.
Two-photon laser scanning microscopy (TPLSM)
After isolating and pressurizing the arteries, TPLSM was
performed as previously described [27,60]. In short, tissue samples
were excited with Tsunami Ti:sapphire laser (Spectra-Physics),
which was pumped by a Millennia Vs 5 W pump laser (Spectra-
Physics) and mode locked at 840 nm, with a 82.5 MHz repetition
rate and 100 fs pulse width. Autofluoresence was visualized at 400
to 450 nm and focal planes were positioned within the tunica
media. Arteries were incubated with Rh-ET-1 (16 nM) and
labeling of structures in the vessel wall was assessed at 620 to
660 nM. Subsequently, the effect of preincubation with BQ123
(1 mM), BQ123 (1 mM) + BQ788 (1 mM) on labeling was
determined. Labeling of arterial smooth muscle in the arterial
wall by Rh-ET-1 (16 nM) can be prevented by ET-1 (16 nM)[2].
Finally, the effects of BQ123 (1 mM), removal of free label and
antagonist and of administration of either CGRP (100 nM) or of
capsaicin (1 mM) on labeling were determined. These experiments
were performed in presence of BQ788 (1 mM)[2].
Figure 5. Unaltered arterial contractile responses to ET-1 (0.25–16 nM) following exposure to CGRP. A, schematic tracings of active wall
tension (WT) versus time (t) illustrating contractile reponses to ET-1 (0.25–16 nM) in arteries transiently treated with (right) or without (left) CGRP
(100 nM). B, schematic tracing of active wall tension (WT) versus time (t) illustrating initial ET-1 effects which were reversed by CGRP before a second
concentration response curve was generated. C: Effect of ET-1 (0.25–16 nM) in arteries pre-treated with CGRP (100 nM, during 16 min). D: Effect of ET-
1 (0.25–16 nM) in arteries in which ET-1-induced contractions were reversed by CGRP (100 nM). n=6. *: p,0.05 vs control.
doi:10.1371/journal.pone.0010917.g005
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Isolated rat mesenteric arteries were canullated, pressurized and mounted under a 2-photon laser scanning microscope. Analyses focussed on the
smooth muscle layer (bordered by the autofluorescent (blue) internal and elastic laminae) (C, G, H)). Experiments were performed in continuous
presence of BQ788 (1 mM) except panels C and D. A and B illustrate schematic tracings of active wall tension versus time illustrating the order of (i)
administration of rhodamine-labeled ET-1 (Rh-ET-1, 16 nM), (ii) application of pharmacological agents and (iii) removal of agonists and antagonists. C,
autofluoresence. D - F, labeling of vascular smooth muscle (D, red) observed in presence of Rh-ET-1 is not noticeably affected by administration of
BQ788 (E, 1 mM) and BQ123 (F, 1 mM). G, autofluorescence. H – J, labeling induced by exposure to Rh-ET-1 (16 nM) persists in absence of free label
and is resistant to ET-receptor antagonists (H) but is rapidly abolished (I) by exposure of the artery to CGRP (100 nM); thereafter labeling of smooth
muscle can be re-established by exposure to Rh-ET-1 (16 nM) (J). K, autofluoresence. L – N, largely similar experiment using capsaicin (CAPS, 1 mM).
Labeling induced by exposure to Rh-ET-1 (16 nM) that persists in absence of free label (L) is abolished (M) by exposure of the artery to CAPS (1 mM);
thereafter labeling of smooth muscle can be re-established by exposure to Rh-ET-1 (16 nM) (N). Scale bars: 50 mm. Findings are representative for 4
arteries of 3 rats.
doi:10.1371/journal.pone.0010917.g006
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Contractile responses are expressed as percentage of the
maximal contractile response to 10 mM NE in absence of
pharmacological inhibitors (NEmax). Relaxing responses are
expressed as percentage reduction of the level of pre-contraction.
Concentration-response curves (CRC) were fitted to a non-linear
sigmoid regression curve (Graphpad Prism 5.0). All data are shown
as mean 6 SEM. Statistical significance was assessed using either
one-way ANOVA (comparison of EC50 and Emax) or two-way
ANOVA (comparison of CRCs). Bonferroni’s post-hoc test was
used to compare multiple groups. A P value ,0.05 was considered
statistically significant.
Supporting Information
Figure S1 Partial and reversible reversing effect of the ETA-
receptor antagonist SB234551 on arterial contractile responses to
ET-1 and their persistence. Isolated rat mesenteric resistance
arteries were studied after treatment with capsaicin (1 mM during
20 min.) in the continuous presence of L-NAME (100 mM) and
indomethacin (10 mM). A, responses to 0.25216 nM ET-1 in the
absence (black) and presence of SB234551 (10 nM, red). Note that
SB234551 prevented responses to up to 8 nM ET-1. B, vasomotor
tone after removal of free agonist and antagonist. C, effects of
SB234552 (10 nM) on contractile responses to 8 nM ET-1. D,
Figure 7. Schemes illustrating the interaction of ET-1 with arterial smooth muscle ETA-receptors (A – D) and the influences of
vasodilators. A, Initially, a part of ET-1 binds to a high affinity binding site (H) on an ETA-receptor. B, next, another part of ET-1 binds to a low affinity
binding site (L) of the receptor. Signaling is triggered by the occupied site L and reinforced by the occupied site H. C, while binding of ET-1 to site L is
quasi-irreversible, the binding of ET-1 to site H remains dynamic and can be competed off by low molecular weight antagonists such as BQ123. D,
binding of antagonists is readily reversible after which bivalent binding of ET-1 to the ETA-receptor and cooperative signaling can be re-established. E,
schematic representation of the endothelium (red), arterial smooth muscle (blue) and peri-arterial SMN (green). Endothelium-derived relaxing factors
such as nitric oxide (NO), endothelium-derived hyperpolarizing factor (EDHF) and prostacyclin (PGI2) released upon stimulation of e.g. endothelial
muscarinic receptors (M) by acetylcholine (ACh), counteract the ET-1/ETA contractile effect by their relaxing effect (functional antagonism).
Stimulation of TRPA1-channels by allyl isothiocyanate (AITC) or of TRPV1-channels by capsaicin (CAPS) or rutaecarpine (RUT) leads to release of CGRP.
In addition to functional antagonism, stimulation of post junctional CGRP-receptors causes dissociation of ET-1/ETA-receptor complexes resulting in
termination of thepersistent vasoconstrictor effect of ET-1.
doi:10.1371/journal.pone.0010917.g007
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PLoS ONE | www.plosone.org 9 June 2010 | Volume 5 | Issue 6 | e10917vasomotor tone after removal of free agonist and antagonist. E,
effect of SB234551 (10 nM) on the contractile response initiated
by 8 nM ET-1 and persisting in the absence of the peptide. F,
vasomotor tone after removal of free antagonist. Data are
expressed as % of the maximal response to norepinephrine
(NEmax) prior to exposure to any drug, and are shown as mean 6
SEM (n=6). *, the difference from control is statistically significant
(P,0.05).
Found at: doi:10.1371/journal.pone.0010917.s001 (9.27 MB TIF)
Figure S2 Effects of CGRP and rutaecarpine are endothelium-
independent. Isolated, denuded rat arteries were studied in
presence of L-NAME (100 mM) and indomethacin (10 mM) as
indicated. Arteries were precontracted with 16 nM ET-1. Next,
increasing concentrations of vasodilator compounds were admin-
istered until a maximal effect was observed. Thereafter vasoactive
stimuli were removed from the organ chamber while the recording
of active wall tension continued for .10 min. A, maximal acute
relaxing effects of CGRP and rutaecarpine. B, long-term effects of
CGRP and rutaecarpine. a, time control; b, CGRP; c,
rutaecarpine.
Found at: doi:10.1371/journal.pone.0010917.s002 (8.27 MB TIF)
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